HENDERSON, NV / ACCESSWIRE / March 6, 2019 / OxyContin maker Purdue Pharma is exploring filing for bankruptcy as one of its options to address potentially significant liabilities from thousands of lawsuits alleging the drug maker contributed to the deadly opioid crisis sweeping the U.S. This news is particularly exciting for investors in non-opioid pain treatment companies. Prior to this news, the market has been forecasted to reach $22.6 billion by 2022, growing at a CAGR of 18.0% for the five-year period of 2017-2022. This news alone could increase that figure even larger.
The technology leading the way in non-opioid pain treatment is non-invasive therapies and one developer we like is Endonovo Therapeutics, Inc. (ENDV). The company is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies and has developed a therapy which helps lessen pain without the kind of side effects many other opioid alternatives have. Their non-invasive easy to use SofPulse device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.
We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Cara Therapeutics, Inc. (CARA), GW Pharmaceuticals plc (GWPH), INSYS Therapeutics, Inc. (INSY), and Zogenix, Inc. (ZGNX).
Beyond SofPulse, Endonovo Therapeutics, Inc. (ENDV) (Market Cap: $9.837M; Share Price: $0.02) has several non-invasive therapies tackling everything from pain management to degenerative joint diseases. The company just announced a deal that will add up to $10 million in working capital to their balance sheet which could amplify the company’s already rapid growth.
Take a look at a few major highlights from ENDV’s past year:
Signing two marketing agreements with well-established medical device sales organizationsEstablishment and expansion of a rapidly growing sales departmentThe completion of the purchase price to the seller of the SofPulse TechnologyThe new Roma medical device is on schedule for release in Q1 of 2019
Start your research on ENDV now.
Cara Therapeutics, Inc. (CARA) (Market Cap: $656.394M; Share Price: $16.64) announced completion of enrollment in the KALM-1 Phase 3 trial of KORSUVA™ (CR845/ difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). More than 350 hemodialysis patients with CKD-aP have now been randomized across approximately 60 clinical sites in the United States.
GW Pharmaceuticals plc (GWPH) (Market Cap: $5.62B; Share Price: $172.57) reported impressive numbers highlighted by its strong launch for cannabinoid oil Epidiolex in seizure treatment. Epidiolex generated $4.7 million in sales over two months.
INSYS Therapeutics, Inc. (INSY) (Market Cap: $449.331M; Share Price: $6.05) presented a poster of its initial pharmacokinetic (PK) study of comparative bioavailability of epinephrine nasal spray and EpiPen® in adults with seasonal allergies at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco, California on Feb. 24, 2019.
Zogenix, Inc. (ZGNX) (Market Cap: $2.207B; Share Price: $52.60) recently announced financial results for the fourth quarter and full-year ended December 31, 2018. The company concluded the year with $514.2 million in cash, cash equivalents, and marketable securities.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve-month agreement, and can be canceled at any time by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.